SIRT1, is it a tumor promoter or tumor suppressor?

International Journal of Biological Sciences

Volumn 5, Issue 2, 2009, Pages 147-152

  Deng, Chu Xia ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

DNA damage repair; SIRT1; Tumor promoter; Tumor suppressor

Indexed keywords

APC; ONCOPROTEIN; PROTEIN P53; SIRTUIN 1; TUMOR PROMOTER;

CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CELL DEATH; DNA DAMAGE; DNA REPAIR; GENETIC STABILITY; GROWTH DISORDER; HETEROZYGOSITY; HUMAN; LIFE EXTENSION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

MUS;

ANIMALS; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; SIRTUINS;

EID: 62749133315     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5.147     Document Type: Review

References (54)

1. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004; 73: 417-435.
2. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 2000; 14: 1021-1026.
3. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007; 26: 5489-5504.
4. Lavu S, Boss O, Elliott PJ, et al. Sirtuins - novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov. 2008; 7: 841-853.
5. Haigis MC, Guarente LP. Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006; 20: 2913-2921.
6. Huffman DM, Grizzle WE, Bamman MM, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007; 67: 6612-6618.
7. Bradbury CA, Khanim FL, Hayden R, et al. Histone deacety-lases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005; 19: 1751-1759.
8. Stunkel W, Peh BK, Tan YC, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J. 2007; 2: 1360-1368.
9. Hida Y, Kubo Y, Murao K, et al. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res. 2007; 299: 103-106.
10. Lim CS. SIRT1: Tumor promoter or tumor suppressor? Med Hypotheses. 2006;67: 341-344
11. Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008; 14: 312-323.
12. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001; 107: 149-159.
13. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001; 107: 137-148.
14. Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008; 13: 454-463.
15. Motta MC, Divecha N, Lemieux M, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004; 116: 551-563.
16. Dai JM, Wang ZY, Sun DC, et al. SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity. J Cell Physiol. 2007; 210: 161-166.
17. Wong S, Weber JD. Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem J. 2007; 407: 451-460.
18. Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hyper-methylation. PLoS Genet. 2006; 2: e40.
19. Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004; 305: 390-392.
20. Yuan Z, Zhang X, Sengupta N, et al. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell. 2007; 27: 149-162.
21. Li K, Casta A, Wang R, et al. Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation. J Biol Chem. 2008; 283: 7590-7598.
22. Liang XJ, Finkel T, Shen DW, et al. SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res. 2008; 6: 1499-1506.
23. Ford J, Jiang M, Milner J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 2005; 65: 10457-10463.
24. Kojima K, Ohhashi R, Fujita Y, et al. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun. 2008; 373: 423-428.
25. Chen WY, Zeng X, Carter MG, et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet. 2003; 33: 197-202.
26. Chen WY, Wang DH, Yen RC, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005; 123: 437-448.
27. Zhao W, Kruse JP, Tang Y, et al. Negative regulation of the deacetylase SIRT1 by DBC1. Nature. 2008; 451: 587-590.
28. Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature. 2008; 451: 583-586.
29. Deng CX, Brodie SG. Knockout mouse models and mammary tumorigenesis. Semin Cancer Biol. 2001; 11: 387-394.
30. Cardiff RD, Anver MR, Gusterson BA, et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene. 2000; 19: 968-988.
31. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response, and cancer evolution. Nucleic Acids Res. 2006; 34: 1416-1426.
32. McBurney MW, Yang X, Jardine K, et al. The absence of SIR2alpha protein has no effect on global gene silencing in mouse embryonic stem cells. Mol Cancer Res. 2003; 1: 402-409.
33. Cheng HL, Mostoslavsky R, Saito S, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A. 2003; 100: 10794-10799.
34. Kamel C, Abrol M, Jardine K, et al. SirT1 fails to affect p53-mediated biological functions. Aging Cell. 2006; 5: 81-88.
35. Banks AS, Kon N, Knight C, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008; 8: 333-341.
36. Zhang QJ, Wang Z, Chen HZ, et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res. 2008; 80: 191-199.
37. Pfluger PT, Herranz D, Velasco-Miguel S, et al. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A. 2008; 105: 9793-9798.
38. Firestein R, Blander G, Michan S, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE. 2008; 3: e2020.
39. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004; 23: 2369-2380.
40. Wang RH, Zheng Y, Kim HS, et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell. 2008; 32: 11-20.
41. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003; 425: 191-196.
42. Oberdoerffer P, Michan S, McVay M, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell. 2008; 135: 907-918.
43. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science. 2004; 306: 2105-2108.
44. Benayoun BA, Batista F, Auer J, et al. Positive and negative feedback regulates the transcription factor FOXL2 in response to cell stress: evidence for a regulatory imbalance induced by disease-causing mutations. Hum Mol Genet. 2008; [Epub ahead of print]
45. Wang C, Chen L, Hou X, et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol. 2006; 8: 1025-1031.
46. DePinho RA. The age of cancer. Nature. 2000; 408: 248-254.
47. Pinkston JM, Garigan D, Hansen M, et al. Mutations that increase the life span of C. elegans inhibit tumor growth. Science. 2006; 313: 971-975.
48. Boily G, Seifert EL, Bevilacqua L, et al. SirT1 regulates energy metabolism and response to caloric restriction in mice. PLoS ONE. 2008; 3: e1759.
49. Feige JN, Lagouge M, Canto C, et al. Specific SIRT1 Activation Mimics Low Energy Levels and Protects against Diet-Induced Metabolic Disorders by Enhancing Fat Oxidation. Cell Metab. 2008; 8: 347-358.
50. Spindler SR. Rapid and reversible induction of the longevity, anticancer and genomic effects of caloric restriction. Mech Ageing Dev. 2005; 126: 960-966.
51. Barger JL, Kayo T, Vann JM, et al. A low dose of dietary res-veratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE. 2008; 3: e2264.
52. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007; 450: 712-716.
53. Brunet J, Vazquez-Martin A, Colomer R, et al. BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. Mol Carcinog. 2008; 47: 157-163.
54. Surmacz E. Obesity hormone leptin: a new target in breast cancer? Breast Cancer Res. 2007; 9: 301.